NOX-H94 is a Spiegelmer that targets peptide hormone hepcidin, the key regulator of iron metabolism.
The trial aims to investigate the tolerability and safety of NOX-H94 with an objective to test pharmacokinetic/pharmacodynamic responses to the compound.
In the trial, the patients will be initially given escalating single doses of NOX-H94 and will then be tested with multiple doses.
Both the intravenous and sub-cutaneous routes of administration will be tested.
Noxxon CEO Iain Buchanan said preliminary data from the study indicates NOX-H94 is safe and well tolerated.